Mesenchymal stem cells for cardiac repair: Are the actors ready for the clinical scenario?

Santiago Roura, Carolina Gálvez-Montón, Clémentine Mirabel, Joaquim Vives, Antoni Bayes-Genis

Research output: Contribution to journalReview articleResearchpeer-review

39 Citations (Scopus)


© 2017 The Author(s). For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissue loss. In this field of research, for years we have actively explored innovative biotherapies for cardiac repair. Here, we present a general, critical overview of our experience in using mesenchymal stem cells, derived from cardiac adipose tissue and umbilical cord blood, in a variety of cell therapy and tissue engineering approaches. We also include the latest advances and future challenges, including good manufacturing practice and regulatory issues. Finally, we evaluate whether recent approaches hold potential for reliable translation to clinical trials.
Original languageEnglish
Article number238
JournalStem Cell Research and Therapy
Issue number1
Publication statusPublished - 27 Oct 2017


  • Cardiac adipose tissue
  • Cardiac repair
  • Cell therapy
  • Good manufacturing practice
  • Mesenchymal stem cells
  • Tissue engineering
  • Umbilical cord blood


Dive into the research topics of 'Mesenchymal stem cells for cardiac repair: Are the actors ready for the clinical scenario?'. Together they form a unique fingerprint.

Cite this